2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 561

U-Act-Early Trial 3 Years Follow-up: Radiographic Joint Damage and Use of Bdmards over 5 Years in Early RA Patients Treated-to-Target with Strategies Initiating Tocilizumab, Methotrexate or Their Combination
Abstract Number: 225

U.S. Trends in Hospitalization Rates and Causes and in-Hospital Mortality in Rheumatoid Arthritis Patients, 2000-2014
Abstract Number: 1443

Ultrasonographic Criteria for the Diagnosis of Erosive Rheumatoid Arthritis Disease Using Osteoarthritic Patients As Controls Compared to Validated Radiographic Criteria
Abstract Number: 678

Ultrasonographic Evaluation of Achilles Tendon in Early Axial Spondyloarthropathy: Is There Any Difference between Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthropathy?
Abstract Number: 1632

Ultrasonographic Evaluation of the Enthesis in Patients Affected By Entheropatic Spondiloarthritis. Focus on Distal Enthesis of the Patellar Tendon
Abstract Number: 950

Ultrasonographic Examinations Show Highly Prevalent Abnormalities of Hamstring Tendons in Lyme Arthritis Patients
Abstract Number: 1206

Ultrasonographic Involvement of the Anterior Chest Wall,a Five Years Follow up
Abstract Number: 679

Ultrasonographic Research of the Relationship between Nail Disorders and Peripheral Arthritis or Enthesitis in Patients with Psoriasis and Psoriatic Arthritis
Abstract Number: 2905

Ultrasound Diagnosis of Large Vessel Inflammation in New-Onset Treatment-Naïve GCA Patients Using Fluorine-18-Fluorodeoxyglucose PET/CT As the Reference Standard – a Prospective Study of 86 Patients Suspected of GCA
Abstract Number: 2966

Ultrasound Shows Rapid Reduction of Uric Load during Treat-to-Target Approach in Gout Patients: Results from a Longitudinal Study
Abstract Number: 1198

Ultrasound-Detected Joint Erosions in Rheumatoid Arthritis: What Every Sonographer Should Know
Abstract Number: 2530

Uncovering Clinicians’ Gaps and Attitudes Toward Biosimilars: Impact of a 2-Phase Educational Program
Abstract Number: 2362

Understanding Patients’ Perceptions of Gout
Abstract Number: 1096

Unexpected Association between Health-Related Quality of Life and the Blood Interferon Modular Transcriptional Signatures in Patients with Systemic Lupus Erythematosus
Abstract Number: 1200

Unilateral Ultrasound Scoring Methods for Synovitis in Rheumatoid Arthritis: An Agreement Study Exploring the Most Inflammatory Active Side

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].